Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.37 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.37 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.37 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.37 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.37 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.37 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.37 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.35 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.32 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.32 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.32 |
| ▸ | HTR3D known ✓ | Q70Z44 | 1/20 | 0.32 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 1/20 | 0.32 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8494600 | 1.00 | ELANE (0.40) | ELANESLC6A2SLC6A3PGRAR | |
| SCHEMBL7117137 | 0.99 | ELANE (0.40) | ELANESLC6A2SLC6A3PGRAR | |
| Hydrochloric Acid SCHEMBL7117389 | 0.80 | ELANE (0.35) | ELANESLC6A2SLC6A3SLC6A4KDM4E | |
| Hydrochloric Acid SCHEMBL7125040 | 0.78 | ELANE (0.51) | ELANESLC6A2SLC6A3PGRAR | |
| Hydrochloric Acid SCHEMBL7204551 | 0.75 | DPP4 (0.31) | — | |
| Hydrochloric Acid SCHEMBL7072124 | 0.75 | DPP4 (0.31) | — | |
| SCHEMBL7588588 | 0.73 | DPP4 (0.31) | — | |
| SCHEMBL7128619 | 0.69 | ELANE (0.43) | ELANEMAPTKDM4EALDH1A1HPGD | |
| SCHEMBL7123982 | 0.69 | ELANE (0.43) | ELANEMAPTKDM4EALDH1A1HPGD | |
| SCHEMBL7123976 | 0.69 | ELANE (0.43) | ELANEMAPTKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176642-A1 | Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors | GYORKOS ALBERT (US) | 2003-09-18 | — | — | US | disclosed |
| US-6548638-B2 | Treatment or amelioration of symptoms of adult respiratory distress syndrome, septic shock, and multiple organ failure. | CORTECH, INC. | 2003-04-15 | — | — | US | disclosed |
| US-20020010315-A1 | Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors | GYORKOS ALBERT (US) | 2002-01-24 | — | — | US | disclosed |
| EP-1089752-A4 | ALPHA-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS | CORTECH INC (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1135151-A4 | PEPTOID AND NONPEPTOID CONTAINING ALPHA-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS | CORTECH INC (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1135151-A1 | PEPTOID AND NONPEPTOID CONTAINING ALPHA-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS | Cortech Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6255453-B1 | INHIBITORS OF HUMAN NEUTOPHIL ELASTASE; TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME, SEPTIC SHOCK, MULTIPLE ORGAN FAILURE, PERIODONTAL DISEASE, GLOMERULONEPHRITIS, CYSTIC FIBROSIS; ANTIARTHRTITIC AGENTS | CORTECH, INC. | 2001-07-03 | — | — | US | disclosed |
| EP-1089752-A1 | ALPHA-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS | Cortech Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000032216-A1 | PEPTOID AND NONPEPTOID CONTAINING ALPHA-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS | CORTECH INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| US-6001813-A | Val-pro containing α-keto oxadiazoles as serine protease inhibitors | CORTECH INC. (US) | 1999-12-14 | — | — | US | disclosed |
| US-6001814-A | TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME, SEPSISMULTIPLE ORGAN FAILURE | CORTECH INC. (US) | 1999-12-14 | — | — | US | disclosed |
| WO-1999062538-A1 | ALPHA-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS | CORTECH INC. (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010315-A1 | Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors | ELANE, SERPINB1, HPN | SLC6A2 4077/4885SLC6A3 4061/4885GABRA1 4334/4885 |
| US-20030176642-A1 | Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors | ELANE, SERPINB1, HPN | SLC6A2 4077/4885SLC6A3 4061/4885GABRA1 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.